Brief: ImmunoGen Announces Multi-Target License And Option Agreement With ImmunoBiochem To Develop Next-Generation Antibody-Drug Conjugates

ImmunoGen

24/07/2023 11:33

July 24 (Reuters) - ImmunoGen Inc  IMGN.O :
    * IMMUNOGEN ANNOUNCES MULTI-TARGET LICENSE AND OPTION
AGREEMENT
WITH IMMUNOBIOCHEM TO DEVELOP NEXT-GENERATION ANTIBODY-DRUG
CONJUGATES
    * IMMUNOGEN INC - IMMUNOBIOCHEM TO RECEIVE AN UPFRONT
PAYMENT AND
IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND TIERED ROYALTIES
    * IMMUNOGEN INC - AGREEMENT REINFORCES IMMUNOGEN'S
COMMITMENT TO
PIPELINE EXPANSION
    * IMMUNOGEN INC - AGREEMENT GRANTS IMMUNOGEN AN EXCLUSIVE
LICENSE
TO EXISTING ANTIBODIES GENERATED BY IMMUNOBIOCHEM
    * IMMUNOGEN INC -  AGREEMENT GRANTS IMMUNOGEN AN OPTION TO
EXPAND
PARTNERSHIP TO INCORPORATE ADDITIONAL TARGETS

Source text for Eikon:  ID:nBw679Dya 
Further company coverage:  IMGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))